{"title":"Clinical efficacy of etonogestrel implants on relieving dysmenorrhea in endometriosis and adenomyosis women for up to 3 years.","authors":"Yinghua Li, Dingheng Li, Ting Feng, Chunfen Wang","doi":"10.3389/fmed.2025.1460578","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dysmenorrhea and menstrual disorders caused by endometriosis (EM) and adenomyosis (AM) have significantly affected the quality of life of a large number of women. As a highly effective clinical contraceptive measure, etonogestrel implants have been previously reported to relieve dysmenorrhea. However, the dysmenorrhea treatment and menstrual regulation effects of etonogestrel implants in AM and EM patients have not been systematically studied.</p><p><strong>Methods: </strong>This retrospective study followed up 100 patients with etonogestrel implants from May 2015 to October 2016, including 44 patients with EM and 56 patients with AM. The VAS scores of dysmenorrhea, menstrual volume, and related adverse events were measured at 12, 24, and 36 months after etonogestrel implantation in these patients.</p><p><strong>Results: </strong>In 100 EM and AM patients, dysmenorrhea significantly improved, with moderate and severe cases decreasing from 50 to 16 and 0% at 36 months. Amenorrhea increased over time, and frequent bleeding declined. Adverse reactions included weight gain (21%), acne (13%), and decreased sexual desire (10%). Serum CA125 levels dropped, confirming therapeutic efficacy.</p><p><strong>Conclusion: </strong>Etonogestrel implantation significantly alleviated dysmenorrhea symptoms in AM and EM patients.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1460578"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968362/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1460578","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Dysmenorrhea and menstrual disorders caused by endometriosis (EM) and adenomyosis (AM) have significantly affected the quality of life of a large number of women. As a highly effective clinical contraceptive measure, etonogestrel implants have been previously reported to relieve dysmenorrhea. However, the dysmenorrhea treatment and menstrual regulation effects of etonogestrel implants in AM and EM patients have not been systematically studied.
Methods: This retrospective study followed up 100 patients with etonogestrel implants from May 2015 to October 2016, including 44 patients with EM and 56 patients with AM. The VAS scores of dysmenorrhea, menstrual volume, and related adverse events were measured at 12, 24, and 36 months after etonogestrel implantation in these patients.
Results: In 100 EM and AM patients, dysmenorrhea significantly improved, with moderate and severe cases decreasing from 50 to 16 and 0% at 36 months. Amenorrhea increased over time, and frequent bleeding declined. Adverse reactions included weight gain (21%), acne (13%), and decreased sexual desire (10%). Serum CA125 levels dropped, confirming therapeutic efficacy.
Conclusion: Etonogestrel implantation significantly alleviated dysmenorrhea symptoms in AM and EM patients.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
